Novo Nordisk CEO Lars Fruergaard Jorgensen has been fielding calls from food company chief executives who have questions about the company's diabetes and weight-loss-related drugs. "They are scared about it," Jorgensen told Bloomberg. The company confirmed to FOX Business he did not name names. However, it is no surprise that these drugs – Ozempic and Wegovy – which are the same medication but have different FDA-approved intended uses and are known to suppress appetites and change food preferences – are cat ...

anilakkus Investment Thesis In this article, I explore Novo Nordisk (NVO). I provide some very relevant information regarding where the company stands with product and the outlook as we begin the 2024 year. There have been major updates with Wegovy and the company’s weight loss drug market, so we will dive into each of them. Despite skepticism about the sustainability of this sector's growth, I maintain a bullish stance. The increasing demand and improved accessibility of GLP-1 drugs along with the very ...

Alexander Spatari/Moment via Getty Images Who would have though Denmark would have been one of the biggest beneficiaries of weight loss drugs? With a weighting of 23% in the iShares MSCI Denmark ETF (BATS:EDEN), it's no wonder that the fund has done well. Of course, this ETF is more than just a single stock, and it's worth exploring the investment case here. EDEN is a fund designed to closely track the investment results of a broad-based index composed of Danish equities. The ETF provides its investors ...

With best-selling medicines for type 2 diabetes and obesity in hand, Novo Nordisk (NVO 2.37%) isn't content to let the chips fall where they may when it comes to patients having access to Ozempic and Wegovy. Thanks to the two drugs becoming a social phenomenon in the developed world, demand is running far above the company's ability to supply doses, potentially crimping its pace of revenue growth.But where there's a shortage, there's money to be made in closing the gap, and that's exactly what Novo Nordisk ...

Danish pharmaceutical company Novo Nordisk (NVO 2.37%) just made the headlines for something other than Ozempic. Well, sort of. One of the company's subsidiaries, Novo Holdings, is responsible for deploying capital in a mission-driven, efficient way to help broaden Novo Nordisk's reach.Earlier this week, Novo Holdings announced it was acquiring Catalent for a total enterprise value of $16.5 billion. Let's break down the deal and analyze why this transaction could be a game changer for Novo Nordisk in the lo ...

At the start of 2020, Novo Nordisk (NVO 0.89%) was worth around $150 billion. Today, its market capitalization is north of $500 billion as it is now one of the most valuable healthcare companies in the world.A big part of that reason is the rising popularity of two drugs: Ozempic and Wegovy. Both have been associated with helping patients shed significant amounts of weight. Thanks to social media, demand for the treatments has been through the roof, and that has sent the stock to new heights.But just how de ...

A major acquisition by its controlling shareholder pushed Novo Nordisk's (NVO 4.01%) U.S.-listed shares 4% higher on Monday. As a result of the deal, Novo Nordisk will acquire from that shareholder (Novo Holdings) three fill-finish sites currently operated by the acquisition target. The jump in Novo Nordisk's share price contrasted quite positively with the S&P 500 index's 0.3% slump for the session.Parent company buying Catalent in a deal worth $16.5 billionOn Monday morning, Novo Holdings revealed that it ...

Novo Nordisk (NVO) announced that it will acquire three manufacturing sites from Novo Holdings A/S for an upfront payment of $11 billion to expand its manufacturing capacity for obesity treatments.The announcement comes pursuant to Novo Holdings’ agreement to acquire global contract development and manufacturing organization Catalent, Inc. (CTLT) for $63.50 per share in cash.Novo Nordisk expects the acquisition to increase its filling capacity from 2026 onward. The three manufacturing sites (out of Catalent ...

Two of the most talked-about drugs in the U.S., obesity treatment Wegovy and diabetes medication Ozempic, are made by the same company: Denmark-based Novo Nordisk (NVO -1.80%). There wouldn't be so much chatter if these drugs weren't flying off pharmacy shelves these days, particularly in the case of Wegovy.Solid evidence of this was provided early this week by the company, which released highly encouraging quarterly and annual results featuring plenty of high-growth figures. Let's pick these apart a little ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks w ...